本文選題：莉芙敏 + 圍絕經(jīng)期綜合征　； 參考：《福建中醫(yī)藥大學(xué)》2014年碩士論文

【摘要】：目的：本課題采用對(duì)莉英敏治療腎陰虛圍絕經(jīng)期綜合征的療效分析,探討莉芙敏對(duì)腎陰虛證型圍絕經(jīng)期綜合征的臨床治療效果,并通過(guò)對(duì)治療效果與血清Beta-膠原特殊序列(Beta-crosslaps, β-crosslaps)水平的相關(guān)性分析,了解莉芙敏對(duì)腎陰虛圍絕經(jīng)期綜合征患者的療效與骨吸收水平的關(guān)系。 方法：1.研究對(duì)象：納入符合西醫(yī)圍絕經(jīng)期綜合征診斷標(biāo)準(zhǔn)、中醫(yī)腎陰虛證診斷標(biāo)準(zhǔn)并知情同意的患者,再根據(jù)排除標(biāo)準(zhǔn)及剔除標(biāo)準(zhǔn)進(jìn)行篩選,最終本課題共收入腎陰虛型圍絕經(jīng)期綜合征患者46例,其中23例為莉芙敏治療組,另外23例為空白對(duì)照組。 2.研究方法：藥物干預(yù)組予口服莉芙敏1片／次,一天2次,連續(xù)服用12周,空白對(duì)照組未予相關(guān)藥物治療。藥物干預(yù)組及空白對(duì)照組在觀察期間均保持生活方式基本不變。在治療前對(duì)所收入的兩組腎陰虛圍絕經(jīng)期綜合征患者進(jìn)行腎陰虛癥狀量化評(píng)估,測(cè)血清卵泡刺激素(Folicle stimulating hormone, FSH)、黃體生成素(Luteinizing hormone,LH)、雌二醇(Estradiol, E2)、β-crosslaps水平。在治療后再次對(duì)所收入的兩組患者進(jìn)行腎陰虛癥狀量化評(píng)估。 結(jié)果：1.腎陰虛癥狀積分與FSH及β-crosslaps有相關(guān)性(P0.05),均呈低度正相關(guān)(相關(guān)系數(shù)0.4)。腎陰虛癥狀積分與LH、E2水平無(wú)相關(guān)性(P0.05)。 2.治療前莉芙敏治療組與空白對(duì)照組的腎陰虛癥狀積分之間的差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05),治療后兩組間腎陰虛癥狀積分和療效指數(shù)之間的差異有統(tǒng)計(jì)學(xué)意義(P0.05)。莉芙敏治療組總有效率為95.65%,空白對(duì)照組總有效率為4.35%。 3.藥物干預(yù)組療效指數(shù)與β-crosslaps有相關(guān)性(P0.05),呈中度負(fù)相關(guān)(0.4相關(guān)系數(shù)0.7)。藥物干預(yù)組療效指數(shù)與FSH、LH、E2無(wú)相關(guān)性(P0.05)。 4.所有研究對(duì)象在服藥期間均未出現(xiàn)過(guò)敏反應(yīng)和其他不良反應(yīng)。 結(jié)論：腎陰虛癥狀與骨吸收水平及FSH水平呈低度正相關(guān)。莉芙敏對(duì)于腎陰虛型圍絕經(jīng)期綜合征患者治療效果明顯,莉芙敏干預(yù)組療效指數(shù)與β-crosslaps為中度負(fù)相關(guān),治療過(guò)程中未發(fā)現(xiàn)不良反應(yīng),臨床上治療腎陰虛圍絕經(jīng)期綜合征患者時(shí)可選擇本藥,對(duì)于骨吸收水平較高的患者可考慮聯(lián)合或改用其他方法治療。
[Abstract]:Objective: to analyze the therapeutic effect of Liyingmin in the treatment of peri-menopausal syndrome of kidney yin deficiency syndrome, and to explore the clinical effect of Lifemin treatment on peri-menopausal syndrome of kidney yin deficiency syndrome. The relationship between the therapeutic effect and the serum levels of Beta-crosslaps (尾 -crosslaps) in patients with kidney yin deficiency perimenopausal syndrome and bone resorption was analyzed. Method 1: 1. Subjects: the patients who met the criteria for diagnosis of perimenopausal syndrome in Western medicine and the diagnosis criteria of deficiency of kidney yin in traditional Chinese medicine with informed consent were selected according to the criteria of exclusion and elimination. Finally, 46 cases of peri-menopausal syndrome of kidney yin deficiency type were included in this study, 23 of them were treated with Livemin and the other 23 were blank control group. 2. Methods: in the drug intervention group, one tablet was given orally, twice a day, for 12 weeks, but the blank control group was not treated with related drugs. The life style of drug intervention group and blank control group remained basically unchanged during the observation period. Before treatment, two groups of patients with kidney yin deficiency peri-menopausal syndrome were evaluated quantitatively for the symptoms of kidney yin deficiency. The serum levels of follicle stimulating hormone Folicle stimulating, FSHH, luteinizing hormone, estradiol, E2P, 尾 -crosslaps were measured. After treatment, the patients in the two groups were evaluated quantitatively for the symptoms of kidney yin deficiency. The result is 1: 1. There was a correlation between the symptom score of kidney yin deficiency and FSH and 尾 -crosslaps (P 0.05), both of which were low positive correlation (correlation coefficient 0. 4). There was no correlation between the symptom score of kidney yin deficiency and the level of LHG E 2. 2. Before treatment, there was no significant difference between Lifemin treatment group and blank control group in the symptom score of kidney yin deficiency (P 0.05), but there was significant difference between the two groups after treatment (P 0.05). The total effective rate was 95.65 in Lifemin treatment group and 4.35 in blank control group. 3. In the drug intervention group, there was a correlation between the therapeutic effect index and 尾 -crosslaps (P 0.05), with a moderate negative correlation of 0. 4 and 0. 7% (P < 0. 05). There was no correlation between the curative effect index and FSHLHN E 2 in the drug intervention group (P 0.05). 4. No allergic reactions or other adverse reactions were observed in all subjects during medication. Conclusion: there is a low correlation between kidney yin deficiency and bone resorption and FSH level. Lifmin was effective in the treatment of peri-menopausal syndrome of kidney yin deficiency type. The efficacy index of Li-min intervention group was negatively correlated with 尾 -crosslaps, and no adverse reactions were found during the treatment. In clinical treatment of kidney yin deficiency perimenopausal syndrome patients can choose this drug, for the patients with high bone resorption level may consider combining or using other treatment.
【學(xué)位授予單位】：福建中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類(lèi)號(hào)】：R711.75

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 付斐;金濤;沈艷紅;曲怡;馬文珠;;推拿治療女性更年期潮熱汗出31例臨床觀察[J];北京中醫(yī)藥;2012年03期

2 李文;孫寧霞;陳旭;郎滌飛;金志軍;;早期子宮內(nèi)膜癌患者術(shù)后應(yīng)用黑升麻制劑治療絕經(jīng)相關(guān)癥狀[J];第二軍醫(yī)大學(xué)學(xué)報(bào);2012年05期

3 肖菊層;;按摩治療更年期綜合征38例臨床體會(huì)[J];光明中醫(yī);2007年01期

4 楊任遠(yuǎn);;針刺結(jié)合六味地黃丸治療婦女更年期綜合征100例[J];光明中醫(yī);2012年01期

5 趙國(guó)慶;趙曉玲;;引火湯治療女性更年期潮熱出汗[J];甘肅中醫(yī)學(xué)院學(xué)報(bào);2008年04期

6 易偉蓮;呂俊廷;歐超偉;;老年男性骨質(zhì)疏松癥與性激素和細(xì)胞因子的檢測(cè)及其臨床意義[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2010年07期

7 劉剛;盧光t;;β-Crosslaps和PINP在絕經(jīng)后婦女骨質(zhì)疏松診斷中的效能評(píng)價(jià)[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2010年08期

8 陳倩;王會(huì)中;高德祿;;老年女性骨質(zhì)疏松癥患者骨代謝生化指標(biāo)的研究[J];國(guó)際檢驗(yàn)醫(yī)學(xué)雜志;2011年20期

9 Eckehard Liske;馬曉艷;白文佩;;圍絕經(jīng)期綜合征的植物療法:兼論黑升麻的研究[J];國(guó)際婦產(chǎn)科學(xué)雜志;2010年04期

10 馬曉艷;張慧;王珂;楊立元;朱賽楠;濮鳴亮;秦麗華;白文佩;;莉芙敏對(duì)去卵巢大鼠下丘腦視前區(qū)5-HT1AR和5-HT2AR表達(dá)的影響[J];國(guó)際婦產(chǎn)科學(xué)雜志;2011年02期

，

本文編號(hào)：1972664